A Phase 1 interventional study of CC-97540 and Fludarabine in Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy and Systemic Sclerosis, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Active, not recruiting at 46 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb — 5 open to participants now, 9 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Bristol-Myers Squibb.
Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, this one is the 7th largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2023, is one of 7 in phase 1, and was the 13th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →5 of the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States
Ages 18–75
Bristol-Myers Squibb · Sites in United States, Argentina, Brazil and 10 more countries
Ages 16+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Bristol-Myers Squibb
Ages 4–75
Bristol-Myers Squibb · Sites in United States, Belgium, France and 3 more countries
Ages 18+
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 8 · Phase 3 4 · Phase 4 1
First in 2005; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 270 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 125 across the 19 interventional studies, 223 across the 1 observational. Of the 11 that completed or were terminated, 7 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company is the lead sponsor of 17 studies on the registry; 12 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- Diagnosis of Systemic Lupus Erythematosus (SLE) defined as follows:.
i) Fulfilling the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria of SLE.
ii) Presence of anti-dsDNA, anti-histone, anti-chromatin, anti-Ro (anti-SS-A), anti-La (anti-SS-B), or anti-Sm antibodies at screening.
- SLE disease activity:.
i) Active disease at screening, with recent ≥ 1 major organ system with a BILAG A score (excluding musculoskeletal, mucocutaneous, and/or constitutional organ system).
ii) Inadequate response to and to at least 2 of the following treatments, used for at least 3 months each: cyclophosphamide, mycophenolic acid or its derivatives, belimumab, azathioprine, anifrolumab, methotrexate, rituximab, obinutuzumab, cyclosporin, tacrolimus or voclosporin.
Diagnosis of Idiopathic Inflammatory Myopathy (IIM) defined as follows:.
i) Fulfilling the 2017 EULAR/ACR classification criteria for probable or definite IIM.
ii) Participant diagnosed with the following IIM subgroups: dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and polymyositis (PM).
iii) Presence of at least 1 myositis specific antibody (MSA), associated antibody (MAA), or ANA at screening or prior to screening.
IIM disease activity:.
i) Severe/moderate muscle AND/OR skin involvement.
ii) Proof of activity as documented by:.
A. An active myositis-associated rash OR.
B. A recent muscle OR.
C. An elevated CK > 3 times the OR.
D. Participants diagnosed IIM AND progressive Interstitial Lung Disease (ILD) on high-resolution computed tomography (HRCT)
iii) Inadequate response to glucocorticoids and at least 2 of the following treatments used for at least 3 months: azathioprine, methotrexate, cyclosporin A, tacrolimus, MMF, cyclophosphamide, IVIG, JAK inhibitors, and rituximab.
Diagnosis of Systemic Sclerosis (SSc) defined as follows:.
i) Fulfilling 2013 EULAR/ACR classification criteria for SSc.
ii) Antinuclear Antibody (ANA) positive at screening or prior to screening.
- SSc disease activity:.
i) Participants diagnosed with diffuse cutaneous SSc OR diffuse or limited cutaneous SSc AND progressive ILD, AND.
ii) Inadequate response to at least 1 of the following treatments used for at least 3 months: mycophenolate, cyclophosphamide, rituximab, nintedanib, azathioprine, tocilizumab, or intravenous immunoglobulins (IVIG).
- Rheumatoid Arthritis (RA) disease activity:.
i) Minimum of 3 SJC and 3 TJC on a 66/68 joint count (SJC/TJC).
ii) OR participants diagnosed with progressive ILD (interstitial lung disease).
iii) AND Inadequate disease response or intolerance to at least one conventional synthetic disease-modifying antirheumatic drug (DMARD) and as well as ≥ 2 DMARDs with different mechanisms of action from the categories biologic disease-modifying antirheumatic drug (bDMARDs) or targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) for a minimum of 3 months.
A. Participants qualifying on progressive ILD may have exhausted the therapies above OR have demonstrated inadequate disease response or intolerance to at least one of the following treatments used for at least 3 months: mycophenolate, tocilizumab, cyclophosphamide, rituximab, azathioprine, nintedinib, pirfenidone.
Exclusion Criteria
- Diagnosis of drug-induced SLE rather than idiopathic SLE.
- Other systemic diseases (eg, multiple sclerosis, psoriasis, inflammatory bowel disease, etc) are excluded. Participants with type I autoimmune diabetes mellitus, thyroid autoimmune disease, Celiac disease, or secondary Sjögren's syndrome are not excluded.
IIM disease activity:.
i) Other forms of IIM: Inclusion Body Myositis, Amyopathic DM, any form of juvenile myositis.
ii) Myositis other than IIM, eg, drug-induced myositis and PM associated with .
iii) Participants with severe muscle damage (Physician VAS for muscle damage in Myositis Damage Index > 7 cm on a 10 cm scale), permanent weakness due to a non-IIM cause (eg, stroke), or myositis with cardiac involvement.
- SSc disease activity:.
i) SSc related PAH requiring active treatment.
ii) Rapidly progressive SSc related lower GI (small and large intestines) involvement (requiring parenteral nutrition); active gastric antral vascular ectasia.
iii) Prior scleroderma renal crisis.
- RA disease activity:.
i) Prior history of or current inflammatory joint disease other than RA.
ii) Joint damage and/or deformity that may confound the investigator's ability to accurately assess disease activity.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CC-97540 · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Tocilizumab
Specified dose on specified days
Also known as: BMS-986353
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Number of participants with treatment-emergent adverse events (AEs) in each indication.
Time frame: Up to 2 years after CC-97540 infusion
Number of participants with serious AEs (SAEs) in each indication.
Time frame: Up to 2 years after CC-97540 infusion
Number of participants with AEs of special interest (AESI) in each indication.
Time frame: Up to 2 years after CC-97540 infusion
Number of participants with laboratory abnormalities in each indication.
Time frame: Up to 2 years after CC-97540 infusion
Number of participants with Dose Limiting Toxicities (DLT) in each indication.
Time frame: Up to 2 years after CC-97540 infusion
Recommended Phase 2 Dose (RP2D) of CC-97540 in each indication.
Time frame: Up to 2 years after CC-97540 infusion
Proportion of participants achieving definition of remission in SLE (DORIS) remission
SLE Cohort
Time frame: At week 24
Proportion of participants achieving Lupus Low Disease Activity State (LLDAS)
SLE Cohort
Time frame: At week 24
Change in proteinuria measured by urine protein creatinine ratio (UPCR)
SLE Cohort
Time frame: At week 24
Change in Health Assessment Questionnaire - Disability Index (HAQ-DI)
Time frame: At week 24
Proportion of participants achieving Myositis Response Criteria (MRC) Total Improvement Score (TIS) Major Response
IIM Cohort
Time frame: At Week 24
Change in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Only Dermatomyositis (DM) participants in the IIM Cohort
Time frame: At Week 24
Proportion of participants with ILD with no worsening of pulmonary function including forced expiratory volume (FEV1) (> 10%), forced vital capacity (FVC) (> 10%), and diffusing capacity of the lung for carbon monoxide (DLCO) (> 15%)
IIM Cohort
Time frame: At Week 24
Proportion of participants achieving a minimal clinically important difference (MCID) of 24% change from baseline of the modified Rodnan Skin Score (mRSS)
SSc Cohort
Time frame: At Week 24
Participants with an improvement from baseline of the Revised Composite Response Index in Systemic Sclerosis (CRISS)
SSc Cohort
Time frame: At Week 24
The worsening of pulmonary function including FVC (>10% absolute), DLCO (>15% absolute decline) in participants with interstitial lung disease (ILD)
SSc Cohort
Time frame: At Week 24
Proportion of participants achieving low Disease Activity Score-28 Joint C-Reactive Protein (DAS28-CRP)
RA cohort
Time frame: At week 24
Proportion of participants achieving simplified disease activity index (SDAI) remission
RA cohort
Time frame: At week 24
Proportion of participants with ILD with no worsening of pulmonary function including FVC (> 10%)
RA cohort
Time frame: At week 24
Maximum observed blood concentration (Cmax)
Time frame: Up to 2 years
Time of maximum observed blood concentration (Tmax)
Time frame: Up to 2 years
Area under the blood concentration-time curve from time zero to 28 days after dosing (AUC(0-28D))
Time frame: Up to 2 years
Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See Plan Description
Access criteria: See Plan Description
Data sharing details ↗ · www.bms.com
Started Sep 2023 (actual). Primary completion is estimated for Aug 2028, 59 months after the start.
Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 59 months is above that.
Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zolacabtagene autoleucel
Lupus Erythematosus, Systemic →
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company →